Gilead should ditch remdesivir and focus on its simpler and safer ancestor
As someone who has been on the corporate side of this type of debate, I can assure you that Gilead has several magnitudes of more information about both of these molecules than the author has.And as others have mentioned, the only data for the alternative molecule is animal data versus remdesivir which already has phase 3 data.  Sure, the other drug might be better, but it might not work at all.